Cumberland Pharmaceuticals (CPIX) Q4 2024 earnings summary

Executive summary

• Achieved strong financial and operational progress in 2024, with 11.6% Q4 revenue growth and full-year net revenues of $38 million.

• Expanded portfolio through acquisitions, international partnerships, and FDA approvals, driving share valuation growth.

• Advanced clinical pipeline, notably with ifetroban for Duchenne muscular dystrophy, and expanded Medicaid coverage for Kristalose.

• 2024 marked by expanded product labeling, key FDA designations, and new study publications.

• Ended 2024 with $76 million in total assets, $18 million in cash, $53 million in liabilities, and $23 million in shareholders' equity.

Financial highlights

• Q4 2024 net revenue was $10.4 million, up 11.6% year-over-year; full-year net revenue reached $38 million.

• Full-year product revenue: Kristalose $15.3M, Sancuso $9M, Vibativ $7.2M, Caldolor $5M.

• Q4 operating expenses were $12.3M (down from $15.5M); full-year operating expenses $44.3M (down from $49.1M).

• Net loss for Q4 was $1.9M; full-year net loss $6.4M; adjusted full-year loss $1.0M.

• Basic and diluted loss per share for 2024 was $(0.46); adjusted diluted loss per share was $(0.07).

Outlook and guidance

• Expects double-digit revenue growth and positive cash flow from operations in 2025.

• Ongoing acquisition initiative to add complementary FDA-approved brands.

• Anticipates continued momentum from approved brands, international partnerships, and clinical programs.

• Focus remains on driving growth, delivering stakeholder value, and advancing the mission into 2025.

• Ongoing clinical programs in systemic sclerosis and pulmonary fibrosis, with continued progress expected.